Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of elF4E expression

摘要

Lung cancer is the leading cause of cancer-related death worldwide. Bromodomain and extraterminal domain (BET) proteins act as epigenome readers for gene transcriptional regulation. Among BET family members, BRD4 was well studied, but for its mechanism in non-small cell lung carcinoma has not been elucidated. elF4E regulates gene translation and has been proved to play an important role in the progression of lung cancer. In this study, we first confirmed that BET inhibitors JQ1 and I-BET151 suppressed the growth of NSCLCs, in parallel with downregulated elF4E expression. Then we found that knockdown of BRD4 expression using siRNAs inhibited the growth of NSCLCs as well as decreased elF4E protein levels. Moreover, overexpression of elF4E partially abrogated the growth inhibitory effect of JQ1, while knockdown of elF4E enhanced the inhibitory effect of JQ1. Furthermore, JQ1 treatment or knockdown of BRD4 expression decreased elF4E mRNA levels and inhibited its promoter activity by luciferase reporter assay. JQ1 treatment significantly decreased the binding of elF4E promoter with BRD4. Finally, JQ1 inhibited the growth of H460 tumors in parallel with downregulated elF4E mRNA and protein levels in a xenograft mouse model. These findings suggest that inhibition of BET by JQ1,1-BET151, or BRD4 silencing suppresses the growth of non-small cell lung carcinoma through decreasing elF4E transcription and subsequent mRNA and protein expression. Considering that BET regulates gene transcription epigenetically, our findings not only reveal a new mechanism of BET-regulated elF4E in lung cancer, but also indicate a novel strategy by co-targeting elF4E for enhancing BET-targeted cancer therapy.